Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 5/2010

Open Access 01-10-2010 | Original Article

Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice

Authors: Ornella Letari, Catherine Booth, Albino Bonazzi, Paolo Garofalo, Francesco Makovec, Lucio C. Rovati, Gianfranco Caselli

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2010

Login to get access

Abstract

Purpose

Gastrointestinal mucositis, commonly associated with diarrhea, is a dose-limiting toxicity of chemotherapy. The new benzamidine derivative CR3294 reduces tissue damage in animal models of intestinal inflammation. Thus, we tested whether CR3294 had the potential to prevent chemotherapy-induced mucositis.

Methods

In tests on isolated cells, reactive oxygen species (ROS) formation and cytokine release were measured by chemiluminescence and immunoassays, respectively. In studies in vivo, BDF1 mice were given oral CR3294 (2.5–20 mg/kg) for 3 days before receiving 5-fluorouracil. Intestinal crypt survival, cell apoptosis and proliferation, and diarrhea score were assessed. Additionally, nude mice bearing tumor xenografts were treated with CR3294 and/or 5-fluorouracil, and tumor growth was monitored.

Results

CR3294 significantly inhibited cytokine release from stimulated leukocytes at concentrations similar to the IC50 (2.9 ± 0.2 μM) for ROS production by these cells. Consistent with these molecular findings, CR3294 dose-dependently protected the intestinal mucosa against 5-fluorouracil-induced toxicity in a mouse model of mucositis. The number of surviving crypts per cross-section in mice receiving 20 mg/kg CR3294 was 2.8-fold that in vehicle-treated animals (18.1 ± 1.9 vs. 6.5 ± 0.9, P < 0.001). Moreover, CR3294 decreased the cumulative diarrhea score by 50%, reduced by nearly 70% the incidence of severe episodes, and increased by 3-fold the number of mice without diarrhea. CR3294 neither affected the growth of tumor xenografts nor protected tumors from the cytotoxic activity of 5-fluorouracil.

Conclusions

This study demonstrates that CR3294 acts on key molecular targets to reduce the signs of mucositis and the occurrence of diarrhea in mice exposed to the chemotherapy drug 5-fluorouracil.
Literature
1.
go back to reference Duncan M, Grant G (2003) Oral and intestinal mucositis—causes and possible treatments. Aliment Pharmacol Ther 18:853–874CrossRefPubMed Duncan M, Grant G (2003) Oral and intestinal mucositis—causes and possible treatments. Aliment Pharmacol Ther 18:853–874CrossRefPubMed
2.
go back to reference Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMed Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMed
3.
go back to reference Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMed Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMed
4.
go back to reference Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13:1303–1311PubMed Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13:1303–1311PubMed
5.
go back to reference Arnold RJ, Gabrail N, Raut M, Kim R, Sung JC, Zhou Y (2005) Clinical implications of chemotherapy-induced diarrhea in patients with cancer. J Support Oncol 3:227–232PubMed Arnold RJ, Gabrail N, Raut M, Kim R, Sung JC, Zhou Y (2005) Clinical implications of chemotherapy-induced diarrhea in patients with cancer. J Support Oncol 3:227–232PubMed
6.
go back to reference Wisinski K, Benson A III (2007) Chemotherapy-induced mucositis: focusing on diarrhea. J Support Oncol 5:270–271PubMed Wisinski K, Benson A III (2007) Chemotherapy-induced mucositis: focusing on diarrhea. J Support Oncol 5:270–271PubMed
7.
go back to reference Rothenberg ML, Meropol NJ, Poplin EA, Van CE, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801–3807PubMed Rothenberg ML, Meropol NJ, Poplin EA, Van CE, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801–3807PubMed
8.
go back to reference Bowen JM (2008) Prevention and treatment of regimen-related mucosal toxicity. Recent Patents Anticancer Drug Discov 3:68–75CrossRef Bowen JM (2008) Prevention and treatment of regimen-related mucosal toxicity. Recent Patents Anticancer Drug Discov 3:68–75CrossRef
9.
go back to reference Keefe DM, Sonis ST, Bowen JM (2008) Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 13:511–522CrossRefPubMed Keefe DM, Sonis ST, Bowen JM (2008) Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 13:511–522CrossRefPubMed
10.
go back to reference Tafani M, Schito L, Anwar T, Indelicato M, Sale P, Di VM, Morgante E, Beraldi R, Makovec F, Letari O, Caselli G, Spadafora C, Pucci B, Russo MA (2008) Induction of autophagic cell death by a novel molecule is increased by hypoxia. Autophagy 4:1042–1053PubMed Tafani M, Schito L, Anwar T, Indelicato M, Sale P, Di VM, Morgante E, Beraldi R, Makovec F, Letari O, Caselli G, Spadafora C, Pucci B, Russo MA (2008) Induction of autophagic cell death by a novel molecule is increased by hypoxia. Autophagy 4:1042–1053PubMed
11.
go back to reference Makovec F, Zanzola S, Artusi R, Rovati LC (2007) Benzamidine derivatives having anti-inflammatory and immunosuppressive activity. Patent No. US7,202,277 Makovec F, Zanzola S, Artusi R, Rovati LC (2007) Benzamidine derivatives having anti-inflammatory and immunosuppressive activity. Patent No. US7,202,277
13.
go back to reference Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62:33–41CrossRefPubMed Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62:33–41CrossRefPubMed
14.
go back to reference Leitao RF, Ribeiro RA, Bellaguarda EA, Macedo FD, Silva LR, Oria RB, Vale ML, Cunha FQ, Brito GA (2007) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 59:603–612CrossRefPubMed Leitao RF, Ribeiro RA, Bellaguarda EA, Macedo FD, Silva LR, Oria RB, Vale ML, Cunha FQ, Brito GA (2007) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 59:603–612CrossRefPubMed
15.
go back to reference Al-Dasooqi N, Gibson RJ, Bowen JM, Keefe DM (2009) Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol 64:1–9CrossRefPubMed Al-Dasooqi N, Gibson RJ, Bowen JM, Keefe DM (2009) Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol 64:1–9CrossRefPubMed
16.
go back to reference (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58:109–113 (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58:109–113
17.
go back to reference Withers HR, Elkind MM (1970) Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med 17:261–267CrossRefPubMed Withers HR, Elkind MM (1970) Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med 17:261–267CrossRefPubMed
18.
go back to reference Potten CS, Hendry JH (1985) The microcolony assay in mouse small intestine. In: Potten CS, Hendry JH (eds) Cell clones. Churchill Livingstone, Edinburgh, pp 50–60 Potten CS, Hendry JH (1985) The microcolony assay in mouse small intestine. In: Potten CS, Hendry JH (eds) Cell clones. Churchill Livingstone, Edinburgh, pp 50–60
19.
go back to reference Potten CS, Rezvani M, Hendry JH, Moore JV, Major D (1981) The correction of intestinal microcolony counts for variation in size. Int J Radiat Biol Relat Stud Phys Chem Med 40:321–326CrossRefPubMed Potten CS, Rezvani M, Hendry JH, Moore JV, Major D (1981) The correction of intestinal microcolony counts for variation in size. Int J Radiat Biol Relat Stud Phys Chem Med 40:321–326CrossRefPubMed
20.
go back to reference Merritt AJ, Jones LS, Potten CS (1996) Apoptosis in murine intestinal crypts. In: Cotter TG, Martin SJ (eds) Techniques in apoptosis. Portland Press, London, pp 269–300 Merritt AJ, Jones LS, Potten CS (1996) Apoptosis in murine intestinal crypts. In: Cotter TG, Martin SJ (eds) Techniques in apoptosis. Portland Press, London, pp 269–300
21.
go back to reference Potten CS, Owen G, Roberts SA (1990) The temporal and spatial changes in cell proliferation within the irradiated crypts of the murine small intestine. Int J Radiat Biol 57:185–199CrossRefPubMed Potten CS, Owen G, Roberts SA (1990) The temporal and spatial changes in cell proliferation within the irradiated crypts of the murine small intestine. Int J Radiat Biol 57:185–199CrossRefPubMed
22.
go back to reference Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMed Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMed
23.
go back to reference Sonis ST, O’Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170–176CrossRefPubMed Sonis ST, O’Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170–176CrossRefPubMed
24.
go back to reference Murphy CK, Fey EG, Watkins BA, Wong V, Rothstein D, Sonis ST (2008) Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res 14:4292–4297CrossRefPubMed Murphy CK, Fey EG, Watkins BA, Wong V, Rothstein D, Sonis ST (2008) Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res 14:4292–4297CrossRefPubMed
25.
go back to reference Facorro G, Sarrasague MM, Torti H, Hager A, Avalos JS, Foncuberta M, Kusminsky G (2004) Oxidative study of patients with total body irradiation: effects of amifostine treatment. Bone Marrow Transplant 33:793–798CrossRefPubMed Facorro G, Sarrasague MM, Torti H, Hager A, Avalos JS, Foncuberta M, Kusminsky G (2004) Oxidative study of patients with total body irradiation: effects of amifostine treatment. Bone Marrow Transplant 33:793–798CrossRefPubMed
26.
go back to reference Braun S, Hanselmann C, Gassmann MG, auf dem Keller U, Born-Berclaz C, Chan K, Kan YW, Werner S (2002) Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 22:5492–5505CrossRefPubMed Braun S, Hanselmann C, Gassmann MG, auf dem Keller U, Born-Berclaz C, Chan K, Kan YW, Werner S (2002) Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 22:5492–5505CrossRefPubMed
27.
go back to reference Lalla RV, Schubert MM, Bensadoun RJ, Keefe D (2006) Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer 14:558–565CrossRefPubMed Lalla RV, Schubert MM, Bensadoun RJ, Keefe D (2006) Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer 14:558–565CrossRefPubMed
28.
go back to reference Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM (2007) VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 9:1449–1454 Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM (2007) VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 9:1449–1454
29.
go back to reference Smith CL, Geier MS, Yazbeck R, Torres DM, Butler RN, Howarth GS (2008) Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model if intestinal mucositis in rats. Nutr Cancer 60:757–767CrossRefPubMed Smith CL, Geier MS, Yazbeck R, Torres DM, Butler RN, Howarth GS (2008) Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model if intestinal mucositis in rats. Nutr Cancer 60:757–767CrossRefPubMed
30.
go back to reference Whitford EJ, Cummins AG, Butler RN, Prisciandaro LD, Fauser JK, Yazbeck R, Lawrence A, Cheah KY, Wright TH, Lymn KA, Howarth GS (2009) Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther 8(6):505–512 Whitford EJ, Cummins AG, Butler RN, Prisciandaro LD, Fauser JK, Yazbeck R, Lawrence A, Cheah KY, Wright TH, Lymn KA, Howarth GS (2009) Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther 8(6):505–512
31.
go back to reference Cheah KY, Howarth GS, Yazbeck R, Wright TH, Whitford EJ, Payne C, Butler RN, Bastian SE (2009) Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. Cancer Biol Ther 8:382–390PubMed Cheah KY, Howarth GS, Yazbeck R, Wright TH, Whitford EJ, Payne C, Butler RN, Bastian SE (2009) Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. Cancer Biol Ther 8:382–390PubMed
32.
go back to reference You WC, Hsieh CC, Huang JT (2009) Effect of extracts from indigowood root (Isatis indigotica Fort.) on immune responses in radiation-induced mucositis. J Altern Complement Med 15:771–778CrossRefPubMed You WC, Hsieh CC, Huang JT (2009) Effect of extracts from indigowood root (Isatis indigotica Fort.) on immune responses in radiation-induced mucositis. J Altern Complement Med 15:771–778CrossRefPubMed
33.
go back to reference Ijiri K, Potten CS (1987) Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer 55:113–123PubMed Ijiri K, Potten CS (1987) Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer 55:113–123PubMed
34.
go back to reference Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL (1998) Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58:933–939PubMed Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL (1998) Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58:933–939PubMed
35.
go back to reference Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B (2001) Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 7:1111–1117CrossRefPubMed Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B (2001) Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 7:1111–1117CrossRefPubMed
36.
go back to reference Yorimitsu T, Klionsky DJ (2005) Autophagy: molecular machinery for self-eating. Cell Death Differ 12(Suppl 2):1542–1552CrossRefPubMed Yorimitsu T, Klionsky DJ (2005) Autophagy: molecular machinery for self-eating. Cell Death Differ 12(Suppl 2):1542–1552CrossRefPubMed
37.
go back to reference Saltz LB (2003) Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 1:35–46PubMed Saltz LB (2003) Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 1:35–46PubMed
38.
go back to reference Benson AB III, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O’Dorisio TM, Vokes EE, Wadler S (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918–2926CrossRefPubMed Benson AB III, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O’Dorisio TM, Vokes EE, Wadler S (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918–2926CrossRefPubMed
39.
go back to reference Potten CS (1996) Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time. Stem Cells 14:452–459CrossRefPubMed Potten CS (1996) Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time. Stem Cells 14:452–459CrossRefPubMed
40.
go back to reference Gibson RJ, Bowen JM, Keefe DM (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116:464–470CrossRefPubMed Gibson RJ, Bowen JM, Keefe DM (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116:464–470CrossRefPubMed
Metadata
Title
Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice
Authors
Ornella Letari
Catherine Booth
Albino Bonazzi
Paolo Garofalo
Francesco Makovec
Lucio C. Rovati
Gianfranco Caselli
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-1224-1

Other articles of this Issue 5/2010

Cancer Chemotherapy and Pharmacology 5/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine